HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Steffin, B Articles by Schopohl, J Search for Related Content PubMed PubMed Citation Articles by Steffin, B Articles by Schopohl, J

Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly

Medizinische Klinik Innenstadt, Department of Endocrinology, University of Munich, Munich, Germany and ¹ Department of Endocrinology, Academic Hospital Bogenhausen, Technical University of Munich, Munich, Germany

(Correspondence should be addressed to B Steffin; Email: birgit.steffin{at}med.uni-muenchen.de)

Object: Treatment with somatostatin analogues (SA) not only inhibits GH secretion but may also impair insulin secretion. In order to evaluate the influence of SA on glucose metabolism, we investigated insulin resistance (IR) and ß-cell function, using the recommended combination of homeostatic model assessment of IR (HOMA-IR) and ß-cell function (HOMA-ß).

Design and methods: This is a prospective, cross-sectional study. We measured fasting insulin, blood glucose and IGF-I. Insulin and blood glucose measurements were taken 120 min after an oral glucose tolerance test with 75 g glucose. We studied 51 patients (27 female/24 male, age 54 years (20–75)). Eighteen patients were on Lanreotide Autogel (LA) treatment, 33 had no medical treatment. GH-levels of more than 2.5 ng/ml was reached by 59% of the patients, 74.5% had normal IGF-I levels.

Results: We found no significant influence of disease activity on HOMA-IR and HOMA-ß. In the 33 of 51 subjects without any drug treatment, median HOMA-ß was 170.4% (36.0–624.0%). In contrast, in the 18 patients on LA treatment, median HOMA-ß was found to be significantly lower (84.2% (36.5–346.2%); P = 0.001). Despite this, there was no difference in HOMA-IR in both groups (2.4 (0.7–8.4) vs 2.3 (0.7–6.1); P < 0.001) despite similar insulin values.

Conclusion: In conclusion, we found that LA decreases ß-cell function significantly without affecting IR. Therefore, we think that insulin secretagogues are probably more effective in the treatment of diabetes mellitus in acromegalic patients on LA therapy than insulin sensitizers.

This article has been cited by other articles:

				G. Mazziotti, I. Floriani, S. Bonadonna, V. Torri, P. Chanson, and A. Giustina Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1500 - 1508. [Abstract] [Full Text] [PDF]

				A. Colao, R. S. Auriemma, M. Galdiero, P. Cappabianca, L. M. Cavallo, F. Esposito, L. F. S. Grasso, G. Lombardi, and R. Pivonello Impact of Somatostatin Analogs Versus Surgery on Glucose Metabolism in Acromegaly: Results of a 5-Year Observational, Open, Prospective Study J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 528 - 537. [Abstract] [Full Text] [PDF]